Results 111 to 120 of about 53,199 (230)
Transplant Infectious Disease, EarlyView.During the 2023–2024 Argentine dengue outbreak, 33 patients with hematological disease showed high complication rates, frequent hospitalization (64%), severe thrombocytopenia (90%), and 6% dengue‐attributable mortality. Transfusion‐associated cases were documented.
Gustavo Adolfo Méndez +16 more
wiley +1 more source
Apoptotic induction of bortezomib.
, 2016 A,C) Bortezomib treated chondrosarcoma cells showed a significantly higher level of caspase 3/7 activity than untreated cells. Untreated control cells served as reference value (ratio = 1). B,D) Cleavage of caspase-3 was detected after 24 h of bortezomib
Nicole Stuendl (310419) +5 more
core +1 more source
Transplant Infectious Disease, EarlyView.Among 135 cases of post‐liver transplant HHV8 disease (4 from NSW), presentations varied, and mortality was high (44%). Donor screening was rare, and donor‐derived infection was suspected in 33%. Survival improved with mTORi, reduced immunosuppression, chemotherapy, and, for non‐KS disease, donor screening. ABSTRACT Background Human herpesvirus 8 (HHV8)
Karen M. J. Waller +12 more
wiley +1 more source
POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley +1 more source
European Journal of Haematology, Volume 117, Issue 4, Page 787-798, October 2026.ABSTRACT Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low‐dose cytarabine, hydroxyurea, or supportive care, with
Antonella Bruzzese +11 more
wiley +1 more source
Multiple myeloma is an incurable plasma cell malignancy. Most patients end up relapsing and developing resistance to antineoplastic drugs, like bortezomib. Antibiotic tigecycline has activity against myeloma.
Irene Gómez-Delgado +28 more
core +1 more source
Bortezomib in multiple myeloma
, 2012 Multiple myeloma (MM) remains an incurable disease, and novel agents are therefore needed to improve outcome. Bortezomib is the first proteasome inhibitor to be approved by the US Food and Drug Administration and the European Agency for the Evaluation of
San Miguel, Jesús F. +1 more
core +1 more source
European Journal of Haematology, Volume 117, Issue 4, Page 995-1006, October 2026.ABSTRACT Multiple myeloma (MM) is an incurable malignancy of terminally‐differentiated plasma cells that represents a major clinical challenge despite unprecedented therapeutic advances, particularly for patients with cytogenetically‐defined high‐risk MM (HR‐MM).
Niamh McAuley +10 more
wiley +1 more source
Bortezomib in multiple myeloma
, 2008 Background: Bortezomib is a novel, first-in-class proteasome inhibitor that has improved outcomes in multiple myeloma, with manageable toxicities. Objective: To summarise the chemistry, pharmacokinetics and metabolism of bortezomib, and review its ...
Roussou, Maria +3 more
core +1 more source